Project Details
| Short title | MK-3475-B49 |
|---|---|
| Acronym | Keynote-B49 |
| Status | Active |
| Effective start/end date | 20/06/21 → 27/05/26 |
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer
- Sabanathan, Dhanusha (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
Project: Research